DrugsControl Media Services
DrugsControl.org

News Detail

India paves way for a cheaper anti-TB drug for kids (22-07-2024)

New Delhi, 22 July 2024: The Indian Patent Office’s rejection of Johnson & Johnson’s (J&J) application for the paediatric version of its anti-tuberculosis (TB) drug, bedaquiline, is likely to have broader implications for access to cost-effective TB treatment,......
View Details

Source : The Hindustan Times
Indian Patent Office Johnson & Johnson anti-tuberculosis drug bedaquiline drug-resistant TB

Related News